Fundraising Fox

Nilo Therapeutics

4 known investors

nilotx.com ↗

Nilo Therapeutics develops immunomodulation therapies that target brain-body neural circuits controlling systemic inflammation, aiming to treat autoimmune and inflammatory diseases. Its approach is focused on restoring immune homeostasis in conditions with large unmet medical need.

BiotechDeep TechHealthtech

Investors · 4

The Column GroupSan Francisco · $30M
DCVC Bioreported · 2 sourcesPalo Alto
Lux Capitalreported · 2 sourcesNew York · $100K – $100M

Also in the syndicate · 1

Gates Foundation

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Salestoolssalestools.io · Oct 2025Nilo Therapeutics Launches with $101M to Target Immune Diseaseclinicaltrialvanguard.com · Oct 2025Nilo Therapeutics Raises $101M in Series A Financingfinsmes.com · Oct 2025Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer - BioSpacebiospace.com · Oct 2025Venture firms pour $101M into a biotech using the brain to fix the immune system | BioPharma Divebiopharmadive.com · Oct 2025Immunology biotech Nilo launches with $101M and mission to harness neural circuitsfiercebiotech.com · Oct 2025

Frequently asked questions

What does Nilo Therapeutics do?
Nilo Therapeutics develops immunomodulation therapies that target brain-body neural circuits controlling systemic inflammation, aiming to treat autoimmune and inflammatory diseases. Its approach is focused on restoring immune homeostasis in conditions with large unmet medical need.
Who are Nilo Therapeutics's investors?
Nilo Therapeutics's investors include The Column Group, DCVC Bio, Lux Capital.